中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Self-Adjuvanting Lipoprotein Conjugate alpha GalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern

文献类型：期刊论文

作者Wang, Jian3; Wen, Yu3; Zhou, Shi-Hao3; Zhang, Hai-Wei2; Peng, Xiao-Qian3; Zhang, Ru-Yan3; Yin, Xu-Guang3; Qiu, Hong1; Gong, Rui2; Yang, Guang-Fu3
刊名JOURNAL OF MEDICINAL CHEMISTRY
出版日期2022-02-10
卷号65期号:3页码:2558-2570
ISSN号0022-2623
DOI10.1021/acs.jmedchem.1c02000
通讯作者Gong, Rui(gongr@wh.iov.cn) ; Yang, Guang-Fu(gfyang@mail.ccnu.edu.cn) ; Guo, Jun(jguo@mail.ccnu.edu.cn)
英文摘要Safe and effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants are the best approach to successfully combat the COVID-19 pandemic. The receptor-binding domain (RBD) of the viral spike protein is a major target to develop candidate vaccines. alpha-Galactosylceramide (alpha GalCer), a potent invariant natural killer T cell (iNKT) agonist, was site-specifically conjugated to the N-terminus of the RBD to form an adjuvant-protein conjugate, which was anchored on the liposome surface. This is the first time that an iNKT cell agonist was conjugated to the protein antigen. Compared to the unconjugated RBD/alpha GalCer mixture, the alpha GalCer-RBD conjugate induced significantly stronger humoral and cellular responses. The conjugate vaccine also showed effective cross-neutralization to all variants of concern (B.1.1.7/alpha, B.1.351/beta, P.1/gamma, B.1.617.2/delta, and B.1.1.529/omicron). These results suggest that the self-adjuvanting alpha GalCer-RBD has great potential to be an effective COVID-19 vaccine candidate, and this strategy might be useful for designing various subunit vaccines.
WOS关键词INVARIANT NKT CELLS ; ANTIBODY-RESPONSES ; VACCINE ; ANTIGEN ; INDUCTION ; AGONISTS ; HELP
资助项目National Natural Science Foundation of China[21772056] ; National Natural Science Foundation of China[22177035] ; National Key Research and Development Program of China[2017YFA0505200] ; Wuhan Bureau of Science and Technology[2020020601012217] ; Wuhan Bureau of Science and Technology[2020020101010001] ; CCNU from the colleges' basic research and operation of MOE[CCNU20TS016] ; Program of Introducing Talents of Discipline to Universities of China (111 program)[B17019]
WOS研究方向Pharmacology & Pharmacy
语种英语
出版者AMER CHEMICAL SOC
WOS记录号WOS:000797933300055
源URL[http://119.78.100.183/handle/2S10ELR8/301352]  
专题新药研究国家重点实验室
通讯作者Gong, Rui; Yang, Guang-Fu; Guo, Jun
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
2.Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, CAS Key Lab Special Pathogens & Biosafety, Wuhan 430071, Peoples R China
3.Cent China Normal Univ, Coll Chem,Hubei Int Sci & Technol Cooperat Base P, Int Joint Res Ctr Intelligent Biosensing Technol, Key Lab Pesticide & Chem Biol,Minist Educ, Wuhan 430079, Peoples R China
推荐引用方式
GB/T 7714		 Wang, Jian,Wen, Yu,Zhou, Shi-Hao,et al. Self-Adjuvanting Lipoprotein Conjugate alpha GalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern[J]. JOURNAL OF MEDICINAL CHEMISTRY,2022,65(3):2558-2570.
APA Wang, Jian.,Wen, Yu.,Zhou, Shi-Hao.,Zhang, Hai-Wei.,Peng, Xiao-Qian.,...&Guo, Jun.(2022).Self-Adjuvanting Lipoprotein Conjugate alpha GalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern.JOURNAL OF MEDICINAL CHEMISTRY,65(3),2558-2570.
MLA Wang, Jian,et al."Self-Adjuvanting Lipoprotein Conjugate alpha GalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern".JOURNAL OF MEDICINAL CHEMISTRY 65.3(2022):2558-2570.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。